Do SGLT2 Inhibitors Decrease Risk for Major Cardiovascular Events in People with T2D?
BACKGROUND AND PURPOSE:
Previous RCTs have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors reduce the incidence of major adverse cardiovascular events in people with type 2 diabetes and previous cardiovascular disease
Observational studies have shown that SGLT2 inhibitors are superior to other antidiabetic drugs for reduction of major CVD events
Filion et al. (BMJ, 2020) compared the risk of cardiovascular events between SGLT2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors, another common antidiabetic drug, among people with type 2 diabetes
Multi-database retrospective cohort study and meta-analysis
Canadian Network for Observational Drug Effect Studies (CNODES) | Administrative healthcare databases
New users of a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin)
Users of a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin)
Users of SGLT2 inhibitors matched to users of DPP-4 inhibitor
Comparisons between groups were calculated using adjusted hazard ratios (HR) and 95% confidence intervals
Site specific results were pooled using random effectsmeta-analysis
Major adverse cardiovascular events (MACE)
Composite of myocardial infarction, ischemic stroke, or cardiovascular death
Please sign up or log in to your ObGFirst to access this Premium Content
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan